Ignite Creation Date:
2025-12-25 @ 1:47 AM
Ignite Modification Date:
2026-05-25 @ 12:28 PM
Study NCT ID:
NCT06001294
Status:
UNKNOWN
Last Update Posted:
2023-08-22
First Post:
2023-08-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
Sponsor:
Xiangcheng Zhang
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Huaian1H
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None